Rare Patient Groups Maintain Positive View of Pharma Industry

Rare Daily Staff

More than half of rare disease patient groups (57 percent) consider the pharmaceutical industry reputation “excellent” or “good,” but don’t believe it’s doing a good job with fair pricing policies or that it’s been helpful to patients in their efforts to gain access to medicine, according to the UK based research group PatientView’s annual Corporate Reputation of Pharma survey.

The industry scored its highest marks with regards to its ability to provide products that benefit rare disease patients with 63 percent of respondents rating the industry as either “excellent” or “good.” That’s up from 51 percent in 2018.

Only 11 percent of respondents rated the industry as “excellent” or “good” with regard to fair pricing practices, and 32 percent gave those same ratings to the industry’s ability to help patients gain access to medicines.

Horizon Therapeutics, Roche, and Takeda enjoyed the best reputation among 34 companies included in the survey.

The survey queried 426 rare disease patient groups throughout the world between November 2022 and February 2023. It assessed corporate reputations across ten categories including patient centricity, patient group relationships, and transparency.